Cellectar Biosciences, ITM enter supply agreement for GMP-grade Ac-225

Cellectar Biosciences (CLRB) and ITM Isotope Technologies Munich announced a supply agreement for Actinium-225, Ac-225. The agreement will support the clinical development of Cellectar’s actinium-labeled phospholipid ether, PLE, radiopharmaceutical candidates, including its Phase 1-ready compound, CLR 121225, for the treatment of solid tumors. CLR 121225, a novel actinium-labeled PLE, is under investigation for the treatment of solid tumors, including pancreatic cancer. Cellectar’s proprietary PLE delivery platform allows for the design and development of novel radiopharmaceuticals that can selectively target and eradicate cancer cells. “Our lead alpha-emitting program, CLR 121225, has demonstrated excellent anti-tumor effects in preclinical studies, especially in pancreatic cancer,” said James Caruso, chief executive officer of Cellectar. “Our agreement with ITM supports our strategic approach to ensure a continuous, high-quality supply of Actinium-225 required to advance our pipeline candidates and to fully explore the potential benefits of this targeted alpha therapy for cancer patients.”